BioStock Studio: Scandion Oncology outlines vision to fight cancer drug resistance

02 December 2020 - 15:56

Scandion Oncology is a Danish biotech company developing treatments aimed at counteracting cancer drug resistance. Currently in phase II with its top candidate SCO-101, the company is raising capital through a rights issue and has partnering in its sights. Scandion Oncology’s CEO Bo Rode Hansen joined BioStock via video link to tell us more about the company and what makes SCO-101 first-in-class drug candidate.  

Watch the full  company presentation and Q&A with Scandion Oncology's CEO Bo Rode Hansen at

This is a press release from BioStock - Connecting Innovation & Capital.

Provided by: Cision
Nasdaq First North GM (Sweden)
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has s...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More